FY2025 EPS Estimate for WAVE Life Sciences Cut by Analyst

Key Points

• Equities research analysts at HC Wainwright have revised their FY2025 EPS estimates for WAVE Life Sciences from ($0.92) to ($0.97), with a consensus expectation of ($1.14) per share for the year.
• Despite the lowered earnings forecast, WAVE Life Sciences has a consensus rating of "Moderate Buy" from analysts, with an average target price of $20.36 per share.
• Insider trading activities showed that Director Gregory L. Verdine sold 30,000 shares, decreasing their position by 9.60%, while company insiders collectively own 23.98% of the stock.

WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) - HC Wainwright cut their FY2025 EPS estimates for WAVE Life Sciences in a research report issued on Thursday, July 31st. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($0.97) per share for the year, down from their prior estimate of ($0.92). The consensus estimate for WAVE Life Sciences' current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for WAVE Life Sciences' FY2028 earnings at $0.20 EPS and FY2029 earnings at $0.72 EPS.

WVE has been the topic of several other research reports. Cantor Fitzgerald assumed coverage on WAVE Life Sciences in a research note on Tuesday, April 29th. They set an "overweight" rating and a $10.00 target price on the stock. Raymond James Financial started coverage on WAVE Life Sciences in a research report on Wednesday, June 11th. They set an "outperform" rating and a $14.00 target price for the company. Canaccord Genuity Group started coverage on WAVE Life Sciences in a research report on Monday. They set a "buy" rating and a $19.00 target price on the stock. Wells Fargo & Company cut their price objective on WAVE Life Sciences from $24.00 to $21.00 and set an "overweight" rating on the stock in a report on Thursday, July 31st. Finally, Wall Street Zen downgraded WAVE Life Sciences from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $20.27.

WAVE Life Sciences Stock Performance

Shares of WAVE Life Sciences stock traded down $0.36 during midday trading on Monday, reaching $8.20. 604,627 shares of the company's stock traded hands, compared to its average volume of 1,302,858. WAVE Life Sciences has a 12 month low of $5.04 and a 12 month high of $16.74. The company has a market cap of $1.30 billion, a PE ratio of -9.10 and a beta of -0.95. The stock has a 50 day moving average of $7.38 and a 200-day moving average of $8.26.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.02). The firm had revenue of $8.70 million for the quarter, compared to the consensus estimate of $11.52 million.

Insider Activity

In related news, Director Gregory L. Verdine sold 30,000 shares of the business's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $6.95, for a total transaction of $208,500.00. Following the completion of the sale, the director directly owned 282,517 shares in the company, valued at approximately $1,963,493.15. The trade was a 9.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 23.98% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of WVE. Adage Capital Partners GP L.L.C. raised its stake in WAVE Life Sciences by 30.1% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 12,516,500 shares of the company's stock valued at $101,133,000 after purchasing an additional 2,894,396 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in WAVE Life Sciences by 63.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,098,866 shares of the company's stock valued at $63,074,000 after buying an additional 1,972,262 shares during the period. Polar Capital Holdings Plc purchased a new stake in shares of WAVE Life Sciences during the 4th quarter worth about $12,370,000. MPM Bioimpact LLC grew its holdings in shares of WAVE Life Sciences by 138.5% during the 4th quarter. MPM Bioimpact LLC now owns 1,489,237 shares of the company's stock worth $18,422,000 after purchasing an additional 864,766 shares during the period. Finally, Driehaus Capital Management LLC boosted its holdings in WAVE Life Sciences by 14.6% in the 4th quarter. Driehaus Capital Management LLC now owns 6,712,449 shares of the company's stock worth $83,033,000 after acquiring an additional 853,589 shares during the period. Institutional investors and hedge funds own 89.73% of the company's stock.

WAVE Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.